Pharsight

Drugs that contain Belzutifan

1. Welireg patents expiration

Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9908845 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(10 years from now)

US9969689 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 13, 2026
Orphan Drug Exclusivity (ODE) Aug 13, 2028

NCE-1 date: 2025-08-13

Market Authorisation Date: 13 August, 2021

Treatment: Treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not r...

Dosage: TABLET;ORAL

More Information on Dosage

WELIREG family patents

Family Patents